Latent Labs raises $50M to advance AI-driven programmable biology
Latent Labs is an AI-driven biotechnology company developing AI foundation models that make biology programmable.
Company name: Latent Labs
Location: London, UK
Industry: Biotechnology
Funding details:
- Amount: $50M (total funding)
- Lead investors: Radical Ventures, Sofinnova Partners
- Additional investors: Flying Fish, Isomer, 8VC, Kindred Capital, Pillar VC
- Notable angel investors: Jeff Dean, Aidan Gomez, Mati Staniszewski
Purpose of investment:
- Accelerate development efforts
- Expand partnerships with biotech and pharmaceutical companies
Leadership:
- CEO & Founder: Simon Kohl
Product:
Latent Labs is an AI-driven biotechnology company developing AI foundation models that make biology programmable.
Key focus areas:
- Generative AI for molecular design, enabling rapid discovery of new molecules
- Computational drug discovery for pharmaceutical applications
- Industrial and environmental biotechnology innovations
Background:
Dr. Simon Kohl, CEO and Founder, was previously co-lead of DeepMind’s protein design team and a senior research scientist on AlphaFold2, one of the most significant AI breakthroughs in protein structure prediction.
Future plans:
With this funding, Latent Labs aims to revolutionize biotechnology by making molecular creation and biological engineering more efficient, scalable, and precise.
